CN102452873A - 含碳或氧同位素化合物、制备方法、应用以及组合物 - Google Patents
含碳或氧同位素化合物、制备方法、应用以及组合物 Download PDFInfo
- Publication number
- CN102452873A CN102452873A CN201010527457XA CN201010527457A CN102452873A CN 102452873 A CN102452873 A CN 102452873A CN 201010527457X A CN201010527457X A CN 201010527457XA CN 201010527457 A CN201010527457 A CN 201010527457A CN 102452873 A CN102452873 A CN 102452873A
- Authority
- CN
- China
- Prior art keywords
- compound
- oxygen
- carbon containing
- carbon
- oxygen isotope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 88
- 229910052799 carbon Inorganic materials 0.000 title claims abstract description 82
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 74
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 70
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 68
- 239000001301 oxygen Substances 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000009826 distribution Methods 0.000 claims abstract description 14
- 230000002503 metabolic effect Effects 0.000 claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 8
- 238000003384 imaging method Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 9
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 150000004032 porphyrins Chemical class 0.000 claims description 8
- 229960000641 zorubicin Drugs 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 7
- 150000002927 oxygen compounds Chemical class 0.000 claims description 6
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 3
- 229960003978 pamidronic acid Drugs 0.000 claims description 3
- 238000009203 neutron therapy Methods 0.000 claims description 2
- 230000001678 irradiating effect Effects 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 230000000155 isotopic effect Effects 0.000 description 15
- 230000009466 transformation Effects 0.000 description 14
- 230000006872 improvement Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 150000001721 carbon Chemical class 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 4
- NTEDWGYJNHZKQW-DGMDOPGDSA-N fluciclovine ((18)F) Chemical compound OC(=O)[C@]1(N)C[C@H]([18F])C1 NTEDWGYJNHZKQW-DGMDOPGDSA-N 0.000 description 4
- 229940027541 fluciclovine f-18 Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 229960004682 cefoperazone Drugs 0.000 description 3
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000009206 nuclear medicine Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000008570 general process Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- NTEDWGYJNHZKQW-UHFFFAOYSA-N 1-amino-3-fluorocyclobutane-1-carboxylic acid Chemical compound OC(=O)C1(N)CC(F)C1 NTEDWGYJNHZKQW-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- -1 amino-acid compounds Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 229960002417 cefoperazone sodium Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000013742 energy transducer activity Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000013002 intravenous (IV) drug Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000009400 out breeding Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical group OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K51/0451—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. phorphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (9)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010527457.XA CN102452873B (zh) | 2010-10-27 | 2010-10-27 | 含碳或氧同位素化合物、制备方法、应用以及组合物 |
US13/244,511 US8709381B2 (en) | 2010-10-27 | 2011-09-25 | Compound containing a carbon or an oxygen isotope, preparation and use thereof, and composition comprising thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010527457.XA CN102452873B (zh) | 2010-10-27 | 2010-10-27 | 含碳或氧同位素化合物、制备方法、应用以及组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102452873A true CN102452873A (zh) | 2012-05-16 |
CN102452873B CN102452873B (zh) | 2014-06-18 |
Family
ID=45997008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010527457.XA Expired - Fee Related CN102452873B (zh) | 2010-10-27 | 2010-10-27 | 含碳或氧同位素化合物、制备方法、应用以及组合物 |
Country Status (2)
Country | Link |
---|---|
US (1) | US8709381B2 (zh) |
CN (1) | CN102452873B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112898107A (zh) * | 2020-04-28 | 2021-06-04 | 新华锦集团有限公司 | 用于制造ri标记化合物的制造方法及制造装置 |
CN114344736A (zh) * | 2021-12-09 | 2022-04-15 | 吉林大学 | 一种包含体内光核反应的肿瘤治疗系统及方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102757017B (zh) * | 2011-04-29 | 2016-04-27 | 北京大基康明医疗设备有限公司 | 含氧同位素化合物、制备方法、应用以及组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080240330A1 (en) * | 2007-01-17 | 2008-10-02 | Holden Charles S | Compact Device for Dual Transmutation for Isotope Production Permitting Production of Positron Emitters, Beta Emitters and Alpha Emitters Using Energetic Electrons |
CN101336114A (zh) * | 2005-12-06 | 2008-12-31 | 通用电气健康护理有限公司 | 使用聚合物的放射性标记方法 |
CN101506128A (zh) * | 2006-08-25 | 2009-08-12 | 国立大学法人岐阜大学 | 高速甲基化法、pet示踪剂制备用试剂盒以及pet用示踪剂的制造方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100312118A1 (en) * | 2009-06-03 | 2010-12-09 | Horzewski Michael J | Systems and Methods for Perfusion Enhanced Diagnostic Imaging |
-
2010
- 2010-10-27 CN CN201010527457.XA patent/CN102452873B/zh not_active Expired - Fee Related
-
2011
- 2011-09-25 US US13/244,511 patent/US8709381B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101336114A (zh) * | 2005-12-06 | 2008-12-31 | 通用电气健康护理有限公司 | 使用聚合物的放射性标记方法 |
CN101506128A (zh) * | 2006-08-25 | 2009-08-12 | 国立大学法人岐阜大学 | 高速甲基化法、pet示踪剂制备用试剂盒以及pet用示踪剂的制造方法 |
US20080240330A1 (en) * | 2007-01-17 | 2008-10-02 | Holden Charles S | Compact Device for Dual Transmutation for Isotope Production Permitting Production of Positron Emitters, Beta Emitters and Alpha Emitters Using Energetic Electrons |
Non-Patent Citations (1)
Title |
---|
JACOBUS A.K. BLOKLAND等: "Positron emission tomography: a technical introduction for clinicians", 《EUROPEAN JOURNAL OF RADIOLOGY》, vol. 44, 31 December 2002 (2002-12-31), pages 70 - 75 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112898107A (zh) * | 2020-04-28 | 2021-06-04 | 新华锦集团有限公司 | 用于制造ri标记化合物的制造方法及制造装置 |
CN114344736A (zh) * | 2021-12-09 | 2022-04-15 | 吉林大学 | 一种包含体内光核反应的肿瘤治疗系统及方法 |
CN114344736B (zh) * | 2021-12-09 | 2022-09-13 | 吉林大学 | 一种包含体内光核反应的肿瘤治疗系统及方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102452873B (zh) | 2014-06-18 |
US20120107238A1 (en) | 2012-05-03 |
US8709381B2 (en) | 2014-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hennrich et al. | [68Ga] Ga-DOTA-TOC: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging | |
Fliegel et al. | 99mTc-tetracycline as a kidney and gallbladder imaging agent | |
Gillings | Radiotracers for positron emission tomography imaging | |
CN106415734B (zh) | 生产43Sc放射性核素及其放射性药物用于正电子发射断层显像 | |
CN102452873B (zh) | 含碳或氧同位素化合物、制备方法、应用以及组合物 | |
McCarthy et al. | Nuclear medicine and positron emission tomography: an overview | |
US4789542A (en) | Radioiodinated glucose analogues for use as imaging agents | |
Ter-Pogossian | Positron emission tomography (PET) | |
Fernandes et al. | Nuclear medicine and drug delivery | |
Maloth et al. | Radioisotopes: an overview | |
Budinger et al. | ‘Positron-emission tomography (PET) | |
Baulieu et al. | Meta-iodobenzylguanidine (MIBG) scintigraphy: A one year experience | |
CN112028914B (zh) | 一种18f-三氟化硼酪氨酸试剂盒及其应用 | |
Jamre et al. | Development of an in vivo radionuclide generator by labeling bleomycin with 191 Os | |
CN1268629C (zh) | 放射性锝-99m标记的异腈类配合物及其制备方法和应用 | |
CN102757017B (zh) | 含氧同位素化合物、制备方法、应用以及组合物 | |
KR102621851B1 (ko) | 포피린 유도체 및 암의 영상화, 진단, 또는 치료용 조성물 | |
Pyles | Production, Purification and Radiochemistry Development of Manganese-52 for Characterization of PET/MR Imaging Agents | |
McAfee et al. | RADIOPHARMACEUTICALS. | |
Chaudhari | Preclinical PET, SPECT, CT, MRI and Optical Imaging in Cancer Research: An Overview. | |
Atkins | Emission tomography | |
Lemos et al. | Alternative PET IEN's radiopharmaceuticals with CV-28 and RDS-111 Cyclotrons | |
CN103880887B (zh) | 一种99mTcO-TYRDTC配合物及其制备方法和应用 | |
El-Gizawy | Comparative studies on the radiolabeling and chromatographic purification of some medically important compounds | |
Harper et al. | Experimental nuclear medicine radiopharmaceutical development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PP01 | Preservation of patent right |
Effective date of registration: 20160831 Granted publication date: 20140618 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PD01 | Discharge of preservation of patent | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20170228 Granted publication date: 20140618 |
|
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20170228 Granted publication date: 20140618 |
|
PD01 | Discharge of preservation of patent | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20190828 Granted publication date: 20140618 |
|
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20190828 Granted publication date: 20140618 |
|
PD01 | Discharge of preservation of patent | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20220828 Granted publication date: 20140618 |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140618 |